Jubilant Life gets US regulator approval for anti-inflammatory drug

Indomethacin capsules are used in treatment of moderate to severe inflammation
Jubilant Life Sciences Ltd today said it has received the final approval for its generic version of non-steroidal anti-inflammatory drug, Indocin, from the US health regulator.

The approval for Indomethacin capsules, generic equivalent of Indocin of Iroko, is for multiple strengths of 25 mg and 50 mg, the company said in a BSE filing.

Indomethacin capsules are used in treatment of moderate to severe inflammation and reduce pain.

"This is the seventh approval that we have received from the USFDA during the current financial year," the company said.

Jubilant Life Sciences has a total of 84 ANDAs for oral solids filed in the US, of which 53 had been approved as on June 30, 2017, it said.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel